|
Quotes & Info
|
| PPHM > SEC Filings for PPHM > Form 8-K on 19-Feb-2013 | All Recent SEC Filings |
19-Feb-2013
Other Events, Financial Statements and Exhibits
On February 19, 2013, Peregrine Pharmaceuticals, Inc. issued a press release providing updated data from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in patients with second-line non-small cell lung cancer.
A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:
Exhibit
Number
99.1 Press Release issued February 19, 2013.
|
|